



Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, April 2nd, 2026
1:05 PM - 3:35 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Samara Stevens, ND; Bridget Bradley, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Jennifer Henderson, DO; Russ Huffman, PMHNP; Tim Langford, PharmD; Eriko Onishi, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Dee Weston

Audience: Jessica Jay*, Vertex; Kathy Sapp*, American Chronic Pain Association; Barby Ingle*, International Pain Fund; Aimee Adelman*, A2A Consulting; Jeff Martin*, Biocryst; Jessica Garrison, Gainwell; Erika Rosie, Vertex; Jeff Krueger, KalVista; Jenna Doerr, Artia Solutions; Lee Stout, Chiesi; Mike Donabedian, Sarepta; Herbert Starr, Acadia; Gary Parenteau, Dexcom; Lewis Backus, OHA; Sejal Upadhyaya, Novo Nordisk; Sergio Mayorga, Concis Labs; Lori Howarth, Bayer; Levi Smith, Vertex; April Grant, Vertex; Ann Nelson, Vertex; Holly Jo Hodges, EOCCO; Melissa Snyder, Gilead; Dan Yeager, Taiho Oncology; Rosalie Elliott, UHA; Tammi Ocumpaugh, Otsuka; Chris Ferrin, IHN; George Homsy; Rod Scott; Jill Carroll, BMS; Norm Navarro, Providence; Mark Kantor, AllCare; Brett Freund; Mark Harmon; Gloria Zepeda; Thomas Wolters, Gainwell; Shauna Wick, Leslie Ayhens, OHA

(*) Provided verbal testimony

I. CALL TO ORDER

- A. Roll Call & Introductions
 - Meeting called to order at approx. 1:05 p.m., introductions by Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and February Minutes presented by Roger Citron, RPh
 - ACTION: Motion to approve, 2nd, all in favor**
- D. Department Update provided by Andrew Gibler, PharmD
- E. Mental Health Clinical Advisory Group Update presented by Andrew Gibler, PharmD



II. CONSENT AGENDA TOPICS

A. Oncology Prior Authorization (PA) Updates

Recommendation:

- Add: Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) to Table 1 in the Oncology Agents PA criteria

III. NEW BUSINESS

A. Analgesics Class Update: Sarah Servid, PharmD

Recommendation:

- Make no changes to the PDL based on review of the clinical evidence
- Update opioid, NSAID, and muscle relaxant PA criteria to align with current evidence for chronic pain conditions
- Evaluate costs in executive session

Public Comment: Jessica Jay, Vertex; Kathy Sapp, American Chronic Pain Association; Barby Ingle, International Pain Fund; Aimee Adelman, A2A Consulting

ACTION: Motion to approve, 2nd, all in favor

B. Lynkuet® (elinzanetant) New Drug Evaluation: Deanna Moretz, PharmD

Recommendations:

- Create a "Neurokinin Receptor Antagonist" PDL class to include both fezolinetant and elinzanetant
- Designate elinzanetant non-preferred and update the PA criteria as proposed

ACTION: Motion to approve, 2nd, all in favor

C. Hereditary Angioedema DERP Report: Sara Fletcher, PharmD

Recommendations:

- Update PA criteria as proposed to include new agents and step through preferred agents
- Evaluate comparative costs in executive session

Public Comment: Jeff Martin, Biocryst

ACTION: Motion to approve, 2nd, all in favor

D. GnRH Agonist and Antagonist Class Update Focused on Pelvic Pain and Dysmenorrhea: Deanna Moretz, PharmD

Recommendations:

- Make no changes to the PDL based on review of the clinical evidence
- Modify the GnRH Agonist and GnRH Antagonist PA criteria as proposed to align with HERC guidance
- Evaluate comparative costs in executive session

ACTION: Motion to approve, 2nd, all in favor



- E. Waskyra™ (etuvetidigene autotemcel) Orphan Drug Evaluation:** Sara Fletcher, PharmD
Recommendations:
- Implement proposed Etuvetidigene Autotemcel PA criteria
ACTION: Motion to approve, 2nd, all in favor
- F. Myalept® (metreleptin) Orphan Drug Evaluation:** Deanna Moretz, PharmD
Recommendations:
- Implement proposed Metreleptin PA criteria to ensure standard of care in patients diagnosed with lipodystrophy due to leptin deficiency
ACTION: Motion to approve, 2nd, all in favor
- G. Cephalosporins Literature Scan:** Kathy Sentena, PharmD
Recommendations:
- make cefaclor and cefpodoxime preferred based on guideline recommendations
- Evaluate comparative costs in executive session
ACTION: Motion to approve, 2nd, all in favor
- H. Acne and Rosacea Class Update:** Deanna Moretz, PharmD
Recommendations:
- Create a new PDL class for rosacea treatments
- Make at least one generic topical metronidazole product approved for management of rosacea preferred
- Make brimonidine non-preferred based on clinical evidence
- Maintain Twyneo and Cabtreo as non-preferred in the rosacea topical medication class
- Make Emrosi non-preferred in the oral tetracycline drug class
- Revise Acne PA criteria to include non-preferred topical agents for management of rosacea and add documentation of baseline assessment of disease severity
- Revise Oral Tetracycline PA criteria to include baseline assessments of acne and rosacea, when prescribed for these indications
- Add renewal criteria to topical acne/rosacea therapies and oral tetracyclines
- Evaluate comparative costs in executive session
ACTION: Motion to approve, 2nd, all in favor

V. EXECUTIVE SESSION

Members Present: Samara Stevens, ND; Bridget Bradley, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Jennifer Henderson, DO; Russ Huffman, PMHNP; Tim Langford, PharmD; Eriko Onishi, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. Analgesics Class

Recommendation: Make tizanidine 2, 4, 6 mg capsules, piroxicam capsules, naproxen sodium capsules, indomethacin ER capsules, diclofenac ER 24H tablets, ketorolac tablets, tramadol ER 24H tablets, lidocaine ointment, capsaicin lotion, acetaminophen (all forms), aspirin-caffeine, acetaminophen-caffeine, and aspirin/acetaminophen/caffeine preferred; make ibuprofen 300 mg tablets, morphine sulfate solution, hydrocodone-acetaminophen solution, codeine sulfate tablet, butorphanol tartrate spray, hydromorphone suppository, opium-belladonna suppository, lidocaine 4% solution, lidocaine 4% cream, hydrocortisone-pramoxine lotion, hydrocortisone-pramoxine ointment, hydrocortisone-pramoxine cream, capsaicin 0.035% cream, and suzetrigine non-preferred. Make all other oral pain formulations containing acetaminophen or aspirin non-preferred

ACTION: Motion to approve, 2nd, all in favor

B. Hereditary Angioedema

Recommendation: Make generic icatibant preferred

ACTION: Motion to approve, 2nd, all in favor

C. GNRH Agonist and Antagonist

Recommendations: Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

D. Cephalosporins

Recommendations: Make cefaclor capsules, cefadroxil capsules, and cefpodoxime tablets preferred

ACTION: Motion to approve, 2nd, all in favor

E. Acne and Rosacea

Recommendations: Make topical generic metronidazole gel and cream preferred and make all other topical rosacea medications non-preferred; and make adapalene cream (brand and generic), benzoyl peroxide (Epsolay) cream, clindamycin phosphate foam, and tretinoin microspheres gel (brand and generic) non-preferred

ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN